Background: Expression of estrogen receptor beta (ER beta) is a potentially interesting prognostic marker and therapeutic target in non-small cell lung cancer (NSCLC). Although the expression of ER beta has been reported to correlate with better prognosis of NSCLC in most literatures, some controversies still exist. Since the limited patient numbers within independent studies, here we performed a meta-analysis to clarify the correlations between ER beta expression and prognosis in NSCLC. Materials and methods: We performed a final analysis of 2279 patients from 14 evaluable studies for Prognostic Value of overexpression ER beta (up to October 2014). Data from eligible studies were extracted and included into meta-analysis using a random effects model. Studies were pooled. Summary hazard ratios (HR) were calculated. Results: Our study shows that the pooled hazard ratio (HR) of overexpression ER beta for overall survival in NSCLC was 0.78 [95% confidence interval (CI): 0.62-0.98] by univariate analysis and 1.06 (95% CI: 0.70-1.61) by multivariate analysis. Pooled HR in American and Japan was 1.09 (95% CI: 0.95-1.25, P=0.239) from 6 studies reported, however, pooled HR was 0.57 (95% CI: 0.46-0.70) outside of American and Japan from 8 studies reported. Pooled HR was 0.75 (95% CI: 0.60-0.94) from 6 studies reported for N-ER beta and 0.76 (95% CI: 0.51-1.12) from 6 Studies reported for C-ER beta. Conclusion: Our results suggested ER beta was significant associated with good overall survival in patients with NSCLC on univariate analysis but not multivariate analysis. ER beta expression is a good prognostic outcome outside of American and Japan. Overexpression of N-ER beta NSCLC patients had better survival. Large prospective studies are now needed to confirm the clinical utility of ER beta as an independent prognostic marker.